Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 14/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1588886 | 1.00 | LIPE (0.56) | LIPEMETAP2HRH3GCGREPHX2 | |
| SCHEMBL12701463 | 0.93 | LIPE (0.64) | LIPEMETAP2HRH3HTR2C | |
| SCHEMBL1589275 | 0.93 | LIPE (0.64) | LIPEMETAP2HRH3HTR2C | |
| SCHEMBL12701607 | 0.91 | LIPE (0.51) | LIPEMETAP2EPHX2 | |
| SCHEMBL1589320 | 0.91 | LIPE (0.51) | LIPEMETAP2EPHX2 | |
| SCHEMBL12724112 | 0.89 | ALDH1A1 (0.44) | LIPEMETAP2HRH3 | |
| SCHEMBL12701474 | 0.86 | LIPE (0.61) | LIPEMETAP2GCGR | |
| SCHEMBL1589408 | 0.86 | LIPE (0.61) | LIPEMETAP2GCGR | |
| SCHEMBL12701783 | 0.85 | LIPE (0.55) | LIPEMETAP2GCGR | |
| SCHEMBL1589504 | 0.85 | LIPE (0.55) | LIPEMETAP2GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440710-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092512-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LPL, MGLL, LIPE | LIPE 3/4885METAP2 985/4885HRH3 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.